Therapeutic agent for diabetes

• US 20060205633A1
• Filed: 05/22/2006
• Published: 09/14/2006
• Est. Priority Date: 11/21/2003
• Status: Abandoned Application

• Current Assignee: Ajinomoto Co., Inc.
• Original Assignee: Ajinomoto Co., Inc.
• Inventors: Nishitani, Shinobu, Takehana, Kenji
• Application Number:
  US11/437,578
• Publication Number:
  US 20060205633A1
• Time in Patent Office: Days
• US Class Current: 514/4.800
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 13/04 for urolithiasis
• CPC Class Codes: A61P 13/06 Anti-spasmodics
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

A pharmaceutical composition herein provided comprises at least one branched chain amino acid selected from the group consisting of isoleucine, leucine and valine, combined with at least one drug selected from the group consisting of anti-diabetic agents, agents for treating or preventing obesity and agents for treating or preventing diabetic complications. This pharmaceutical composition is useful as an agent for preventing and/or treating diabetes, diabetic complications, hyperinsulinemia, sugar dysbolism, or obesity.

Claims

1. A pharmaceutical composition comprising at least one branched chain amino acid selected from the group consisting of isoleucine, leucine and valine, combined with at least one drug selected from the group consisting of anti-diabetic agents, agents for treating or preventing obesity and agents for treating or preventing diabetic complications.

2. The pharmaceutical composition as set forth in claim 1 wherein the anti-diabetic agent is selected from the group consisting of insulin-containing pharmaceutical preparations, insulin derivatives, agents having insulinoid actions, insulin secretion-accelerating agents, insulin resistance-improving agents, biguanide-containing agents, glucogenesis-inhibitory agents, agents for inhibiting the absorption of sugar, agents for inhibiting the renal sugar re-absorption, β

3 adrenalin-receptor agonists, glucagon-like peptide-1, glucagon-like peptide-1 analogues, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase IV inhibitors, glycogen-synthesizing enzyme kinase-3 inhibitory agents and glycogen phosphorylase-inhibitory agents;

the agent for treating or preventing obesity is selected from the group consisting of antilipemics, anorexigenic agents and lipase-inhibitory agents; and

the agent for treating or preventing diabetic complications is selected from the group consisting of hypotensive agents, peripheral circulation-improving agents, antioxidants and agents for treating diabetic neuropathy.

3. The pharmaceutical composition as set forth in claim 1, which is applied to the treatments of diseases caused by the hyperglycemia and used for preventing and/or treating the diseases.

4. The pharmaceutical composition as set forth in claim 1, which is applied to the treatments of diabetes, diabetic complications, hyperinsulinemia, the abnormality of glucose tolerance or obesity and used for preventing and/or treating the diseases.

5. The pharmaceutical composition as set forth in claim 1, wherein the drug is selected from the group consisting of anti-diabetic agents, agents for treating or preventing obesity and combination thereof.

6. The pharmaceutical composition as set forth in claim 1, wherein the drug is an anti-diabetic agent.

7. The pharmaceutical composition as set forth in claim 1, wherein the drug is selected from the group consisting of β

3 adrenalin-receptor agonists, glucagon-like peptide-1, glucagon-like peptide-1 analogues, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase IV inhibitors and anorexigenic agents.

8. The pharmaceutical composition as set forth in claim 1, wherein the drug is selected from the group consisting of insulin-containing pharmaceutical preparations, insulin secretion-accelerating agents, insulin resistance-improving agents, agents for inhibiting the absorption of sugar and agents for inhibiting the renal sugar re-absorption.

9. The pharmaceutical composition as set forth in claim 1, wherein the drug is an insulin-containing pharmaceutical preparation or an insulin secretion-accelerating agent.

10. The pharmaceutical composition as set forth in claim 9, wherein the drug is an insulin-containing pharmaceutical preparation.

11. The pharmaceutical composition as set forth in claim 9, wherein the drug is an insulin secretion-accelerating agent.

12. The pharmaceutical composition as set forth in claim 1, wherein the branched chain amino acid is isoleucine.

13. The pharmaceutical composition as set forth in claim 1, which is in the dosage form comprising 0.1 to 30 g/kg/day of the branched chain amino acid and 0.01 to 20000 mg/kg/day of the drug.

14. The pharmaceutical composition as set forth in claim 13, wherein the branched chain amino acid and the drug are in the form of a single pharmaceutical preparation.

15. The pharmaceutical composition as set forth in claim 13, wherein the branched chain amino acid and the drug are in the form of separate pharmaceutical preparations.